FDA OKs Relistor for opioid patients

Apr 28, 2008

The U.S. Food and Drug Administration has approved Relistor (methylnaltrexone bromide) to help restore bowel function in patients receiving opioids.

The FDA said opioids are often prescribed on a continuous basis for patients with late-stage, advanced illness to help alleviate pain, such as in cases of incurable cancer, heart failure and Alzheimer's disease with dementia.

But opioids can interfere with normal bowel movements by relaxing the intestinal smooth muscles and preventing them from contracting and pushing out waste products. Relistor acts by blocking opioid entrance into the cells, thus allowing the bowels to continue to function normally.

"This new drug will be helpful to patients who experience severe constipation associated with the continuous use of morphine or other opioids, which are an important part of care for patients with late-stage, advanced illness." said Dr. Joyce Korvick, deputy director of the FDA's division of gastroenterology products.

Relistor is manufactured by Wyeth Pharmaceuticals Inc. of Philadelphia and Progenics Pharmaceuticals of Tarrytown, N.Y.

Copyright 2008 by United Press International

Explore further: EU regulator: Morning-after pill OK for all women

add to favorites email to friend print save as pdf

Related Stories

Apple's fiscal 3Q earnings top analyst forecasts

4 hours ago

Apple's growth prospects are looking brighter as anticipation builds for the upcoming release of the next iPhone, a model that is expected to cater to consumers yearning for a bigger screen.

Recommended for you

EU regulator: Morning-after pill OK for all women

7 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

12 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

12 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

Jul 23, 2014

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments : 0